Since 1999, China has entered an aging society. According to the Ministry of Civil Affairs survey in early 2018, the proportion of the elderly over 60 years old in China has reached 17.3%, and the proportion of the elderly population has increased year by year. Dementia is a common problem in the elderly. A domestic study found that the prevalence of dementia in the population over 65 is 5.14%, representing that about one in every 20 elderly people suffer from dementia. Among dementia, Alzheimer's disease (1) was most common, and some studies have shown that there are about 800 to 10 million patients with Alzheimer's disease in China, even if they are slightly recognized. The number of patients with knowledge disorders has reached 24 million. It is estimated that the number of people suffering from the disease will exceed 30 million by 2050. China will be the region with the largest population and the fastest growth rate in the world. Alzheimer's disease seriously threatens the health of the elderly and also gives the family and society. Bring a heavy burden. Due to the lack of effective diagnostic and therapeutic drugs, international pharmaceutical companies have also invested in research and development resources. However, they have faced many failures and no new therapeutic drugs have been introduced.
The first Asian Alzheimer's Disease Clinical Research Forum (CTAD-ASIA) was held in Shanghai on September 2nd. During the meeting, many experts who were concerned about Alzheimer's disease shared their research results. “Xinxu Medicineâ€, which focuses on the development of new drugs for cranial nerve degenerative diseases, shared the strategic goals of future R&D strategy and company development. Dr. Zhang Mingkui, founder and CEO of Xinxu Medicine, said that the first product developed by Xinxu Medicine, “Tau Protein Tracerâ€, has made breakthroughs in the diagnosis and drug efficacy tracking of Alzheimer's disease. Scale to initiate clinical research programs in cooperation with hospitals at home and abroad.
If the Tau protein is not normal, it may cause neurological diseases such as Alzheimer's disease.
What is "Tau protein"? Dr. Zhang Mingkui pointed out that Tau protein is present in the neurons of the brain's central nervous system and plays a very important role. The cellular function of the Tau protein in the normal brain is to bind to the microtubules and maintain the integrity of the cellular structure. When the Tau protein is no longer normal and forms a viscous polymer, it can cause neurological diseases such as Alzheimer's disease and some rare brain diseases such as Frontotempora I Dementia (FTD) and Progressive supranuclear palsy (PSP). Many studies have also found that changes in the amount of abnormal Tau protein have a positive relationship with the severity of these diseases. Therefore, if the Tau protein is used as a starting point for research, there is a chance to find a key way of treatment. Equally important is A rare disease caused by abnormal Tau protein may also find a successful and effective therapy.
In response to the study of Tau protein, Xinxu Medicine has developed the "Tau Protein Tracer": APN-1607, and has carried out clinical research in many countries or regions to detect abnormal Tau protein from the patient's brain. Dr. Zhang Mingkui said that Xinxu Pharmaceutical's APN-1607 can quickly enter the brain through the blood-brain barrier, combine with Tau neurofibrillary tangles, and use positron emission tomography (PET) to show the Tau protein fiber wrapped in the patient's brain. The number and distribution of knots.
Hope to bring more breakthroughs in the treatment of related diseases with Tau protein tracer and related drugs
Dr. Zhang Mingkui added that Tau protein tracer can effectively assist doctors in diagnosis, and can also help drugs in clinical research stage to analyze drug effects, which can be a tool to accelerate the clinical development of new drugs. Compared with other Tau protein tracers, AXI's APN-1607, in addition to the Tau protein expression status of patients with Alzheimer's disease, is currently a rare global brain for Alzheimer's disease. Tracer for accurate interpretation of degenerative diseases.
PET imaging helps to confirm the efficacy of the treatment. Dr. Zhang Mingkui said that this feature of APN-1607 will promote the new drug development strategy of Xinxu Medicine and other pharmaceutical companies to be more flexible in cooperation. Xinxu Pharmaceutical will open APN-1607, which will be used by other pharmaceutical companies and medical research units to make the tracer more widely used. Therefore, we hope to find more solutions to the disease and let patients get more Good treatment.
In addition to the development of tracers, Xinxu Medicine currently includes Tau protein-based research and development products, including small molecules and macromolecules, which are expected to bring more treatment for Alzheimer's disease and other neurodegenerative diseases. breakthrough.
Xinxu Pharmaceutical cooperates with domestic excellent hospitals and will cooperate with Shanghai Huashan Hospital
Hospitals and clinicians are very important partners in clinical research and new drug research and development. Xinxu Medicine and excellent hospitals in important cities such as Shanghai, Beijing, Guangzhou and Wuhan will have specific clinical research projects. Xinxu will launch the APN-1607 clinical research project in cooperation with Huashan Hospital affiliated to Shanghai Fudan University. Professor Hua Yihui, Professor of the PET Center of Huashan Hospital, Professor Zuo Chuantao, and neurologists from Huashan Hospital participated in this research project, and officially launched the first product of Xinxu Pharmaceutical in the Chinese mainland market, in line with the world.
Dr. Zhang Mingkui pointed out that Xinxu Pharmaceutical actively cooperates with domestic hospitals, research institutes and pharmaceutical companies, and hopes to bring more possibilities for domestic patients to access innovative drugs. In the past, if there were new drugs in the international research and development stage, domestic patients were less likely to participate. Even if new drugs have been successfully introduced, the time to enter the domestic market is often late. Xinxu Medicine is based in the Chinese market, but it is hoped that In the clinical research stage, the established medical cooperation network in China allows patients with degenerative diseases of the brain in China to have access to updated diagnosis and treatment, bringing more substantial help to patients and their families.
Our organic vegetable powder mainly used dehydration technology. Dehydration vegetable powder remained most fiber and taste of fresh vegetables, so they are suitable to be added in sauce, stuff, pudding, yogurt and dessert. Some vegetable powder could be applied as pigment like red beet root powder. Some could be mixed with other super green powders to make health formula, kale powder and broccoli powder are always good choice for customers.
Vegetable Powder,Red Beet Root Powder,Broccoli Powder,Organic Vegetable Powder
YT(Xi'an) Biochem Co., Ltd. , https://www.ytlinkherb.com